Woodmont Investment Counsel LLC Reduces Stock Position in Harrow, Inc. (NASDAQ:HROW)

Woodmont Investment Counsel LLC trimmed its position in Harrow, Inc. (NASDAQ:HROW) by 60.7% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 80,955 shares of the company’s stock after selling 124,908 shares during the quarter. Woodmont Investment Counsel LLC owned about 0.23% of Harrow worth $3,640,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Hills Bank & Trust Co acquired a new position in Harrow in the 3rd quarter worth approximately $107,000. Rice Hall James & Associates LLC boosted its holdings in shares of Harrow by 23.1% in the 3rd quarter. Rice Hall James & Associates LLC now owns 314,881 shares of the company’s stock valued at $14,157,000 after acquiring an additional 59,019 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its stake in shares of Harrow by 64.2% in the third quarter. China Universal Asset Management Co. Ltd. now owns 6,825 shares of the company’s stock worth $307,000 after acquiring an additional 2,668 shares during the period. Semanteon Capital Management LP purchased a new position in shares of Harrow during the third quarter worth $686,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its position in Harrow by 21.5% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,283 shares of the company’s stock valued at $57,000 after purchasing an additional 227 shares during the period. Institutional investors and hedge funds own 72.76% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have weighed in on HROW shares. Lake Street Capital increased their price target on Harrow from $45.00 to $55.00 and gave the stock a “buy” rating in a research report on Friday, October 4th. B. Riley reaffirmed a “buy” rating and set a $50.00 target price on shares of Harrow in a report on Thursday, August 29th. Finally, Craig Hallum lifted their price target on Harrow from $45.00 to $65.00 and gave the company a “buy” rating in a research report on Friday, October 4th.

Harrow Trading Up 5.3 %

Shares of Harrow stock opened at $48.24 on Thursday. The firm has a 50-day simple moving average of $46.70 and a two-hundred day simple moving average of $30.57. The company has a market cap of $1.71 billion, a P/E ratio of -50.78 and a beta of 0.76. Harrow, Inc. has a fifty-two week low of $7.60 and a fifty-two week high of $59.23. The company has a debt-to-equity ratio of 3.18, a quick ratio of 2.43 and a current ratio of 2.60.

Harrow (NASDAQ:HROW) last issued its quarterly earnings data on Wednesday, August 7th. The company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.12. The business had revenue of $48.94 million during the quarter, compared to the consensus estimate of $42.78 million. Harrow had a negative net margin of 21.78% and a negative return on equity of 40.59%. As a group, equities analysts predict that Harrow, Inc. will post 0.09 earnings per share for the current fiscal year.

Harrow Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.